Premium
Cytogenetic investigation of chromosomal aberrations in cells treated with plantamajoside from Plantago asiatica
Author(s) -
Koo YunChang,
Jung SungHoon,
Yang JiHee,
Ryu Yungsun,
Kim Eunjin,
Lee KwangWon
Publication year - 2009
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.2802
Subject(s) - genotoxicity , toxicity , traditional medicine , clastogen , cytotoxicity , phytochemical , chromosome aberration , biology , plantaginaceae , pharmacology , toxicology , chemistry , genetics , medicine , in vitro , botany , gene , chromosome , organic chemistry
Abstract Plantago asiatica is a member of the Plantaginaceae family, and is widely distributed in East Asia. In our previous work, a single active compound, plantamajoside was isolated and confirmed to have glycation inhibitory activity, and did not possess toxicity during a 90 day repeated oral toxicity test in rats. In the present study, a chromosomal aberration test was performed to investigate the genotoxicity of plantamajoside. From the results of the cytotoxicity test, plantamajoside proved to be less toxic when it was treated combined with S9 cell fractions. However, there was a significant increase in structural aberrations during the short‐term treatment of plantamajoside at its highest dose (5000 µg/mL) even when combined with S9. This seems to have been a natural phenomenon due to the very high dose of plantamajoside that was used. However, to confirm the safety of plantamajoside for its potential use as a phytochemical agent in health products, additional mutagenicity tests are necessary. Copyright © 2009 John Wiley & Sons, Ltd.